Michael Grissinger spent 22 years at Johnson & Johnson, holding positions of Vice President and Head, Worldwide Pharmaceutical Licensing as well as Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. He has led transactions and teams across a broad span of deal-types, geographies, and therapeutic disease areas. Mr. Grissinger brings to Akari Therapeutics extensive experience in business and corporate development, finance, marketing and strategic planning in the pharmaceutical industry. Prior to joining Johnson & Johnson, Mr. Grissinger spent 20 years in the healthcare industry with Ciba-Geigy and SmithKline Beckman. Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business.
For investor relations inquiries: IR@akaritx.com
For business development inquiries: BD@akaritx.com
EXPANDED ACCESS POLICY
In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.